期刊文献+

Graves病甲亢患者甲状腺摄^(131)I率峰值的影响因素探讨 被引量:3

Factors affecting RAIU in hyperthyroidism patients:an analysis
原文传递
导出
摘要 目的 :分析甲亢患者甲状腺摄1 31 I率峰值的影响因素。方法 :对 10 6例甲亢患者进行甲状腺摄1 31 I率(RAIU)的测定 ,并分析年龄及性别、甲状腺重量、是否服用抗甲状腺药物 (ATD)、服ATD时间及停ATD时间对甲状腺摄1 31 I率峰值的影响。结果 :不同年龄、性别组患者的甲状腺摄1 31 I率峰值无显著性差异 (F =1.6 8,P =0 .14 39)。测定前按要求准备 ,不同服药时间及停药时间组之间的RAIU峰值差异无显著性意义 (F =0 .81,P =0 .5 974 ) ,服ATD组与未服药组无明显差异 (t=1.136 2 ,P =0 .2 6 2 5 )。甲状腺重量≤ 30g的患者较重量 >30g的患者的RAIU峰值差异有显著性 (F =6 .13,P =0 .0 0 2 9)。结论 :年龄、性别对RAIU峰值无影响。只要测定RAIU前停ATD至少一周以上 ,RAIU峰值不受服药、停药时间影响 ,与未服药组所测结果一致。RAIU峰值与甲状腺重量有关 ,重量≤ 30g患者的RAIU峰值小于重量 >30g患者的峰值。 Objective:To analyze the factors affecting thyroid radioiodine uptake(RAIU)of hyperthyroidism patients.Methods:RAIU was performed in 106 hyperthyrodism patients. Some factors were studied to analyze influences on the peak of RAIU, including patients′ age and sex, gland weight, taking antithyroid drugs (ATD)or not, time of ATD taking and withdrawal.Results:Patients′ RAIU peak had no significant difference for different ages and sex ( F=1.68,P =0.1439). If preparation was performed according to the requirements before RAIU measurement,taking ATD or not had no influence on RAIU ( t=1.1362,P =0.2625). RAIU peak was different between patients whose gland weight was≤30?g and >30?g. Conclusions:Age and sex have no influence on RAIU. As long as ATD was discontinued at least one week before RAIU measurement, time of taking ATD and discontinuation have no influence on RAIU, and the result of measurement coincide with that of patients who do not take medicine. RAIU peak has relation with gland weight, and RAIU of people with gland weight ≤30?g was lower than that of people with gland weight >30?g.
出处 《军事医学科学院院刊》 CSCD 北大核心 2003年第1期54-55,共2页 Bulletin of the Academy of Military Medical Sciences
关键词 甲状腺功能亢进 GRAVES病 甲状腺摄131I率 甲状腺拮抗药 甲状腺重量 hyperthyroidism Graves disease thyroid radioiodide uptake (RAIU) antithyroid drug (ATD) gland weight
  • 相关文献

参考文献3

  • 1[1]Sabri O,Zimny M,Schreckenberger M,et al.Success rate of radioiodine therapy in Graves′ disease: the influence of thyrostatic medication[J]. J Clin Endocrinol Metab,1999,84(4):1229-1223.
  • 2[2]Sabri O,Schulz G,Zimny M,et al.Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves′disease[J].Nuklearmedizin,1998,37(3):83-89.
  • 3[3]Chiovato L,Fiore E,Vitti P,et al.Outcome of thyroid function in Graves′ patients treated with radioiodine:role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage[J].J Clin Endocrinol Metab,1998,83(1):40-46.

同被引文献37

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部